Synergy between vancomycin and nafcillin against staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Leonard, Steven N ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAFCILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACILLUS SUBTILIS; BACTERIAL LOAD; BACTERIAL STRAIN; BIOASSAY; BROTH DILUTION; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HETEROGENEOUSLY VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; SIMULATION; STAPHYLOCOCCUS AUREUS; TIME KILL CURVE ANALYSIS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, BIOLOGICAL; NAFCILLIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84864232796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042103     Document Type: Article

References (39)

1. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML, (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38: 448-451.
2. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK, (2006) Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50: 3039-3047.
3. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, et al. (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38: 521-528.
4. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, et al. (2007) Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 45: 1511-1514.
5. Fong RK, Low J, Koh TH, Kurup A, (2009) Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 28: 983-987.
6. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, et al. (2009) Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 199: 619-624.
7. Sakoulas G, Eliopoulos GM, Fowler VG Jr, Moellering RC Jr, Novick RP, et al. (2005) Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 49: 2687-2692.
8. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, et al. (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350: 1670-1673.
9. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, et al. (2008) Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 46: 2950-2954.
10. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML, (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23: 99-139.
11. Bae IG, Federspiel JJ, Miro JM, Woods CW, Park L, et al. (2009) Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 200: 1355-1366.
12. American Thoracic Society and The Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
13. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, et al. (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39: 1267-1284.
14. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52: e56-93.
15. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52: e18-55.
16. Rand KH, Houck HJ, (2004) Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48: 2871-2875.
17. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, et al. (2010) Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 54: 3161-3169.
18. Lin G, Pankuch GA, Ednie LM, Appelbaum PC, (2010) Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother 54: 2201-2205.
19. Climo MW, Patron RL, Archer GL, (1999) Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 43: 1747-1753.
20. Domaracki BE, Evans AM, Venezia RA, (2000) Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother 44: 1394-1396.
21. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP, (2012) In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother 56: 202-207.
22. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, et al. (2003) Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82: 333-339.
23. Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ, (2007) Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 51: 3731-3733.
24. Sieradzki K, Tomasz A, (1997) Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother 39 Suppl A pp. 47-51.
25. Sieradzki K, Tomasz A, (1999) Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 181: 7566-7570.
26. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A, (2003) Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 41: 1687-1693.
27. (2008) Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 8th ed Document M07-A8 Wayne, PA: CLSI.
28. Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ, (2009) Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 53: 805-807.
29. LaPlante KL, Rybak MJ, (2004) Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48: 4665-4672.
30. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, et al. (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98.
31. Standiford HC, Jordan MC, Kirby WM, (1970) Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis 122.
32. Kind AC, Tupasi TE, Standiford HC, Kirby WM, (1970) Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch Intern Med 125: 685-690.
33. Blaser J, (1985) In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15 Suppl A pp. 125-130.
34. Walker CA, Kopp B, (1978) Sensitive bioassay for vancomycin. Antimicrob Agents Chemother 13: 30-33.
35. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA: the journal of the American Medical Association 298: 1763-1771.
36. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E, (2006) Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368: 874-885.
37. Leonard SN, Rybak MJ, (2009) Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 63: 155-160.
38. Rose WE, Knier RM, Hutson PR, (2010) Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother 65: 2149-2154.
39. Turnidge JD, (1998) The pharmacodynamics of beta-lactams. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 27: 10-22.